Bulk Manufacturer of Controlled Substances Registration, 8116-8117 [2019-04025]
Download as PDF
<![CDATA[
8116
Federal Register / Vol. 84, No. 44 / Wednesday, March 6, 2019 / Notices
local laws, and reviewing the company’s
background and history.
Therefore, pursuant to 21 U.S.C.
823(a), and in accordance with 21 CFR
1301.33, the DEA has granted a
registration as a bulk manufacturer to
the above listed company.
Dated: February 18, 2019.
John J. Martin,
Assistant Administrator.
[FR Doc. 2019–04031 Filed 3–5–19; 8:45 am]
BILLING CODE 4410–09–P
Registered bulk manufacturers of
the affected basic classes, and
applicants therefore, may file written
comments on or objections to the
issuance of the proposed registration on
or before May 6, 2019.
ADDRESSES: Written comments should
be sent to: Drug Enforcement
Administration, Attention: DEA Federal
Register Representative/DPW, 8701
Morrissette Drive, Springfield, Virginia
22152.
DATES:
The
Attorney General has delegated his
authority under the Controlled
Substances Act to the Administrator of
the Drug Enforcement Administration
(DEA), 28 CFR 0.100(b). Authority to
exercise all necessary functions with
respect to the promulgation and
implementation of 21 CFR part 1301,
incident to the registration of
manufacturers, distributors, dispensers,
importers, and exporters of controlled
SUPPLEMENTARY INFORMATION:
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA–392]
Bulk Manufacturer of Controlled
Substances Application: S&B Pharma
Inc.
ACTION:
Notice of application.
substances (other than final orders in
connection with suspension, denial, or
revocation of registration) has been
redelegated to the Assistant
Administrator of the DEA Diversion
Control Division (‘‘Assistant
Administrator’’) pursuant to section 7 of
28 CFR part 0, appendix to subpart R.
In accordance with 21 CFR
1301.33(a), this is notice that on
February 28, 2017, S&B Pharma Inc.,
405 South Motor Avenue, Azusa,
California 91702–3232 applied to be
registered as a bulk manufacturer of the
following basic classes of controlled
substances:
Controlled substance
Drug code
Marihuana ................................................................................................................................................................
Tetrahydrocannabinols ............................................................................................................................................
Amphetamine ..........................................................................................................................................................
Methamphetamine ...................................................................................................................................................
Lisdexamfetamine ...................................................................................................................................................
Methylphenidate ......................................................................................................................................................
Pentobarbital ...........................................................................................................................................................
4-Anilino-N-phenethyl-4-piperidine (ANPP) .............................................................................................................
Tapentadol ...............................................................................................................................................................
Fentanyl ...................................................................................................................................................................
The company plans to manufacture
the listed controlled substances in bulk
for use in product development and for
commercial sales to its customers. In
reference to drug codes 7360
(marihuana) and 7370 (THC), the
company plans to bulk manufacture
both as synthetic substances. No other
activity for these drug codes is
authorized for this registration.
Dated: February 18, 2019.
John J. Martin,
Assistant Administrator.
[FR Doc. 2019–04030 Filed 3–5–19; 8:45 am]
BILLING CODE 4410–09–P
The
company listed below applied to be
registered as a bulk manufacturer of
various basic classes of controlled
substances. Information on a previously
published notice is listed below. No
comments or objections were submitted
for the notice.
Drug Enforcement Administration
[Docket No. DEA–392]
Bulk Manufacturer of Controlled
Substances Registration
Notice of registration.
The registrant listed below
has applied for and been granted a
registration by the Drug Enforcement
Administration (DEA) as a bulk
manufacturer of various classes of
schedule I and II controlled substances.
SUMMARY:
Company
FR Docket
Eli-Elsohly Laboratories ........................................................
83 FR 64159 ........................................................................
The DEA has considered the factors in
21 U.S.C. 823(a) and determined that
the registration of this registrant to
manufacture the applicable basic classes
of controlled substances is consistent
with the public interest and with United
States obligations under international
treaties, conventions, or protocols in
VerDate Sep<11>2014
18:35 Mar 05, 2019
Jkt 247001
I
I
II
II
II
II
II
II
II
II
SUPPLEMENTARY INFORMATION:
DEPARTMENT OF JUSTICE
ACTION:
7360
7370
1100
1105
1205
1724
2270
8333
9780
9801
Schedule
effect on May 1, 1971. The DEA
investigated the company’s maintenance
of effective controls against diversion by
inspecting and testing the company’s
physical security systems, verifying the
company’s compliance with state and
local laws, and reviewing the company’s
background and history.
PO 00000
Frm 00046
Fmt 4703
Sfmt 4703
Published
December 13, 2018.
Therefore, pursuant to 21 U.S.C.
823(a), and in accordance with 21 CFR
1301.33, the DEA has granted a
registration as a bulk manufacturer to
the above listed company.
E:\FR\FM\06MRN1.SGM
06MRN1
Federal Register / Vol. 84, No. 44 / Wednesday, March 6, 2019 / Notices
Dated: February 26, 2019.
John J. Martin,
Assistant Administrator.
approval of the information collection
request.
FOR FURTHER INFORMATION CONTACT:
[FR Doc. 2019–04025 Filed 3–5–19; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF LABOR
Agency Information Collection
Activities; Submission for OMB
Review; Comment Request, Reentry
Employment Opportunities Evaluation,
New Collection
Office of the Assistant
Secretary for Policy, Chief Evaluation
Office, Department of Labor.
ACTION: Notice of information collection;
request for comment.
AGENCY:
The Department of Labor
(DOL), as part of its continuing effort to
reduce paperwork and respondent
burden, conducts a preclearance
consultation program to provide the
general public and federal agencies with
an opportunity to comment on proposed
and/or continuing collections of
information in accordance with the
Paperwork Reduction Act of 1995
(PRA95). This program helps to ensure
that requested data can be provided in
the desired format, reporting burden
(time and financial resources) is
minimized, collection instruments are
clearly understood, and the impact of
collection requirements on respondents
is properly assessed. Currently, the
Department of Labor is soliciting
comments concerning the collection of
data about the Reentry Employment
Opportunities Program. A copy of the
proposed Information Collection
Request (ICR) can be obtained by
contacting the office listed in the
addressee section of this notice.
DATES: Written comments must be
submitted to the office listed in the
addressee’s section below on or before
May 6, 2019.
ADDRESSES: You may submit comments
by either one of the following methods:
Email: ChiefEvaluationOffice@dol.gov;
Mail or Courier: Jessica Lohmann, Chief
Evaluation Office, OASP, U.S.
Department of Labor, Room S–2312, 200
Constitution Avenue NW, Washington,
DC 20210. Instructions: Please submit
one copy of your comments by only one
method. All submissions received must
include the agency name and OMB
Control Number identified above for
this information collection. Comments,
including any personal information
provided, become a matter of public
record. They will also be summarized
and/or included in the request for OMB
SUMMARY:
VerDate Sep<11>2014
18:35 Mar 05, 2019
Jkt 247001
Jessica Lohmann by email at
ChiefEvaluationOffice@dol.gov or by
phone at (202) 693–5087.
SUPPLEMENTARY INFORMATION:
I. Background: The information
collection activities described in this
notice will provide data for the Reentry
Employment Opportunities (REO)
program evaluation. As part of the REO
program, DOL awarded $78 million in
Reentry Project (RP) grants in 2018, $73
million in RP grants during 2017, $31
million in Reentry Demonstration
Project grants during 2016, and $21
million in Training to Work grants
during 2015 and 2016. Although each
grant program is distinctive, the
overarching aim of the REO program is
to improve employment outcomes and
workforce readiness for people involved
in the justice system by way of
employment services, case management,
and other supportive services. The REO
program evaluation will involve
grantees that received grants during
2016, 2017, and 2018. The evaluation
will involve an implementation study
and an impact study. The
implementation study will address four
main research questions: (1) How were
programs implemented and what factors
influenced implementation?; (2) What
are the variations in the model,
structure, partnerships, and services of
the REO grants?; (3) How did
implementation vary by organization
type (such as an intermediary
organization that operates in more than
one state or a community-based
organization) and target population?;
and (4) What key program elements
appear to be promising? Research
questions for the impact study include:
(1) What impact do grantees or strategies
implemented by grantees have on
participants’ outcomes, such as
employment and recidivism?; (2) Does
program effectiveness vary by grantee
characteristics, such as population
served and services offered?; and (3) To
what extent do impacts vary across
selected subpopulations, such as age
group and type of offense?
This Federal Register Notice provides
the opportunity to comment on the
following proposed REO evaluation data
collection instruments:
1. Semi-structured inverview
protocols. As part of the implementation
study, which will be conducted in
approximately 28 sites, the evaluation
team will conduct semi-structured
interviews with program administrators,
frontline staff, and partners to
understand how the program
PO 00000
Frm 00047
Fmt 4703
Sfmt 4703
8117
implementation has been developed,
managed, and delivered.
2. Participant focus group protocols.
As part of the implementation study, the
evaluation team will conduct focus
groups to gather information from
participants. Participant focus groups
will ask about participants’ reasons for
enrolling, impressions of the program
and the extent to which it has helped
them prepare for employment.
3. Employer focus group protocols. As
part of the implementation study, the
evaluation team will conduct focus
groups to gather information from
employers. The focus groups with
employers will enable an exploration of
how the grantees are meeting the needs
of employers.
4. Semi-structured telephone
interview protocols. As part of the
implementation study, the study team
will conduct telephone interviews with
approximately 58 sites that were not
visited in person. These semi-structured
interviews with program administrators
will focus on understanding program
implementation, challenges
encountered, and their potential
solutions.
5. Virtual focus group protocols. As
part of the implementation study, the
study team will conduct approximately
15 virtual focus groups, including
approximately 135 REO program
administrators in total. Each focus group
will be topically focused to gather more
in-depth information on a specific
aspect of implementation, such as
participant retention strategies, data
management, or outcomes tracking.
6. Follow-up survey. Approximately 5
grantees will be selected for the impact
study. Among the selected grantees, the
survey will be administered to
approximately 1,890 impact study
participants and will allow us to capture
respondents’ experiences in the program
or in other services since enrollment in
the study while measuring detailed
information about study members’
employment experiences. Specifically,
the survey will collect data about
participants’ employment, earnings,
credential attainment, skills attainment,
recidivism and other topics of interest.
II. Desired Focus of Comments:
Currently, the Department of Labor is
soliciting comments concerning the
above data collection for the REO
Evaluation. DOL is particularly
interested in comments that do the
following:
Æ evaluate whether the proposed
collection of information is necessary
for the proper performance functions of
the agency, including whether the
information will have practical utility;
E:\FR\FM\06MRN1.SGM
06MRN1
]]>Agencies
[Federal Register Volume 84, Number 44 (Wednesday, March 6, 2019)]
[Notices]
[Pages 8116-8117]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2019-04025]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA-392]
Bulk Manufacturer of Controlled Substances Registration
ACTION: Notice of registration.
-----------------------------------------------------------------------
SUMMARY: The registrant listed below has applied for and been granted a
registration by the Drug Enforcement Administration (DEA) as a bulk
manufacturer of various classes of schedule I and II controlled
substances.
SUPPLEMENTARY INFORMATION: The company listed below applied to be
registered as a bulk manufacturer of various basic classes of
controlled substances. Information on a previously published notice is
listed below. No comments or objections were submitted for the notice.
----------------------------------------------------------------------------------------------------------------
Company FR Docket Published
----------------------------------------------------------------------------------------------------------------
Eli-Elsohly Laboratories................. 83 FR 64159................. December 13, 2018.
----------------------------------------------------------------------------------------------------------------
The DEA has considered the factors in 21 U.S.C. 823(a) and
determined that the registration of this registrant to manufacture the
applicable basic classes of controlled substances is consistent with
the public interest and with United States obligations under
international treaties, conventions, or protocols in effect on May 1,
1971. The DEA investigated the company's maintenance of effective
controls against diversion by inspecting and testing the company's
physical security systems, verifying the company's compliance with
state and local laws, and reviewing the company's background and
history.
Therefore, pursuant to 21 U.S.C. 823(a), and in accordance with 21
CFR 1301.33, the DEA has granted a registration as a bulk manufacturer
to the above listed company.
[[Page 8117]]
Dated: February 26, 2019.
John J. Martin,
Assistant Administrator.
[FR Doc. 2019-04025 Filed 3-5-19; 8:45 am]
BILLING CODE 4410-09-P
